Researchers map the peptide behind semaglutide across 25 brain regions in each sex, finding striking differences in ...

Seventy-two years after the first antipsychotic, Thorazine, was approved, psychiatry is now seriously discussing the need to ...

Drug Farm today announced that the U.S. Food and Drug Administration (U.S. Food and Drug Administration, FDA) has accepted DF-003, the company's investigational therapy for ROSAH syndrome, into the ...

Peptilogics, a surgical therapeutics company dedicated to curing and preventing devastating medical device-related infections (MDRI), has announced the enrollment of the first patient in the RETAIN ...

When parts of the small intestine are diseased or die, the treatment can involve surgically removing the affected tissue. Although lifesaving, the procedure—referred to as a radical small bowel ...

Sanofi is betting $1.53 billion on a novel drug from Sino Biopharmaceutical, securing global rights to a first-in-class JAK/ROCK inhibitor that could play a double role in the French pharma’s ...

Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors demonstrated a nearly 50% lower risk for systemic autoimmune rheumatic disease vs. those who received dipeptidyl ...

The drugs have names that sound like small planets: semaglutide, liraglutide, lixisenatide. Collectively, they belong to a class of glucagon-like peptide 1 (GLP-1) analogs that has reshaped the ...

Share on Pinterest Researchers believe that high doses of semaglutide may reduce blood flow to the optic nerve, which could lead to eye stroke. Maria Korneeva/Getty Images A new study has found that ...

Popular GLP-1 receptor agonist drugs (GLP-1 RAs) for weight loss appear to be similarly effective among patients of different ages, races, and starting weight, with women benefiting somewhat more than ...

Researchers create the first sex-specific GLP-1 brain atlas, revealing why weight-loss drugs work differently in men and women.

A sweeping review of dozens of clinical trials suggests that today’s most widely used GLP-1 receptor agonist drugs produce broadly consistent weight-loss results across age, race, ethnicity, and ...